Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 57, Issue 11, Pages 1599-1609Publisher
SPRINGER
DOI: 10.1007/s00262-008-0491-8
Keywords
metastatic renal cell carcinoma; gamma 9 delta 2 T lymphocytes; interleukin-2; clinical efficacy; safety and tolerability
Categories
Funding
- Innate Pharma SAS, Marseille, France
Ask authors/readers for more resources
Purpose gamma 9 delta 2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gamma delta can be selectively expanded in vivo with BrHPP (IPH1101, Phosphostim) and interleukin 2 (IL-2). A phase I Study was conducted in patients with metastatic renal cell carcinoma (mRCC) to determine the maximum-tolerated dose and safety of Innacell gamma delta (TM), an autologous cell-therapy product based on gamma 9 delta 2 T lymphocytes, in patients with mRCC. Experimental design A 1-h intravenous infusion of gamma 9 delta 2 T lymphocytes was administered alone during treatment cycle 1 and combined with a low dose of subcutaneous interleukin-2 (IL-2, 2 MIU/m(2) from Day 1 to Day 7) in the two subsequent cycles (at 3-week intervals). The dose of gamma 9 delta 2 T lymphocytes was escalated from 1 up to 8 x 10(9) cells. Results Ten patients underwent a total of 27 treatment cycles. Immunomonitoring data demonstrate that gamma 9 delta 2 T lymphocytes are initially cleared from the blood to reappear at the end of IL-2 administration. Dose-limiting toxicity occurred in one patient at the dose of 8 x 10(9) cells (disseminated intravascular coagulation). Other treatment-related adverse events (AEs) included mainly gastrointestinal disorders and flu-like symptoms (fatigue, pyrexia, rigors). Hypotension and tachycardia also occurred, especially with co-administered IL-2. Six patients showed stabilized disease. Time to progression was 25.7 weeks. Conclusion The data collected in ten patients with mRCC indicate that repeated infusions of Innacell gamma delta (TM) at different dose levels (up to 8 x 10(9) total cells), either alone or with IL-2 is well tolerated. These results are in favor of the therapeutic value of cell therapy with Innacell gamma delta (TM) for the treatment of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available